zygous hypercholesterolaemias. Curr Opin Lipidol 2004;15:413–422. 34. Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Palmer M, Wilpshaar W. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 2008;197: 400–406. 35. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaud...

Hypercholesterolaemia is one of the major causes of atherosclerosis. Although there are many causes, hypercholesterolaemia is the permissive factor that allows other risk factors to operate. The incidence of coronary heart disease is usually lowwhere population plasma cholesterol concentrations are low. In Britain coronary heart disease is a major cause of mortality, and a recent Department of ...

The CPD paper trail is prohibitively expensive, and the Board has determined that the publishing division must contain costs. I am sorry that my comments came across as ‘hard cheese’ – that was not intended. We had anticipated difficulties with the new process and have not been disappointed. Emily Nel at the SAMA Western Cape Branch has indicated her willingness to enter the questionnaires on b...

1. WHO Familial Hypercholesterolaemia must be treated to prevent coronary artery disease. (Online) 1998. (Cited 1998 Sept 4). Available from URL: http://www.who.int/inf-pr-1998/en/pr98-62.html. 2. Ezzati M, Lopez AD, Rodgers A, Vander Hoom S, Murray CJ, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet2002; 360: 1347-6...

Sir, Argatroban is a synthetic direct thrombin inhibitor that is used as an anticoagulant for haemodialysis (HD) in patients with type II heparin-induced thrombocytopenia (HIT) or with antithrombin III deficiency [1,2]. Although there has been no report of hypercholesterolaemia as an adverse effect of argatroban, I recently experienced a case in which severe hypercholesterolaemia was strongly s...